Beneficient announced it has closed an $8.75 million GP primary capital transaction with Quartus AI Fund LP, managed by Quartus Capital Partners LLC.
The transaction is part of Beneficient’s GP Primary Commitment Program, which provides capital solutions to private investment funds. In exchange for an interest in the fund, Quartus AI Fund received approximately $8.75 million in stated value of Beneficient’s resettable convertible preferred stock, which can be converted into Class A common stock under agreed terms.
Following the transaction, Beneficient expects to benefit from an unrealized gain of approximately $1.2 million tied to its pro rata share of the fund’s existing portfolio. The deal is also projected to increase collateral within the company’s ExAlt loan portfolio by about $9.77 million in alternative asset interests, while adding a similar amount to tangible book value attributable to shareholders.
Quartus AI Fund focuses on growth-stage vertical AI investments targeting real-world applications across high-value sectors. The fund currently holds nine portfolio companies, the majority of which are U.S.-based, and has demonstrated strong performance relative to benchmark indices in recent years.
Beneficient’s GP Primary Commitment Program is designed to address significant demand for primary capital commitments, estimated at up to $330 billion, by supporting fund managers during fundraising while deploying capital into equity positions that enhance the company’s balance sheet and investment exposure.
The transaction aligns with Beneficient’s broader strategy to expand access to liquidity and capital solutions in the alternative asset market, particularly for mid- to high-net-worth individuals, smaller institutions, and general partners seeking flexible financing and exit opportunities.
KEY QUOTE:
“We are pleased to partner with Quartus AI Fund LP and welcome Quartus Capital Partners LLC to our GP Primary Commitment Program. We believe Quartus is an exceptional firm at the forefront of vertical AI investing, and this transaction reflects our continued commitment to closing transactions that drive shareholder value and enhance the value of the collateral backing our ExAlt loan portfolio.”
James Silk, Interim CEO, Beneficient
